Patents by Inventor Christopher Peter Wayman
Christopher Peter Wayman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150072995Abstract: A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.Type: ApplicationFiled: September 24, 2014Publication date: March 12, 2015Applicant: Ixchelsis LimitedInventors: Alasdair Mark Naylor, Rachel Jane Russell, Stephen Derek Albert Street, Kim-Wah Tang, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
-
Publication number: 20110107442Abstract: A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.Type: ApplicationFiled: January 10, 2011Publication date: May 5, 2011Inventors: Alasdair Mark Naylor, Rachel Jane Russell, Stephen Derek Albert Street, Kim-Wah Tang, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
-
Publication number: 20090175793Abstract: A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.Type: ApplicationFiled: December 19, 2008Publication date: July 9, 2009Inventors: Alasdair Mark Naylor, Rachel Jane Russell, Stephen Derek Albert Street, Kim-Wah Tang, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
-
Patent number: 7432299Abstract: Use of an alpha-2-delta ligand, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of premature ejaculation.Type: GrantFiled: December 2, 2003Date of Patent: October 7, 2008Assignee: Pfizer Inc.Inventors: Charles Price Taylor, Jr., Andrew John Thorpe, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman, David Juergen Wustrow
-
Publication number: 20060052435Abstract: The use of a composition comprising a selective dopamine D3 receptor agonist, wherein said dopamine D3 receptor agonist is at least about 15-times more functionally selective for a dopamine D3 receptor as compared with a dopamine D2 receptor when measured using the same functional assay, in the preparation of a medicament for the treatment and/or prevention of sexual dysfunction.Type: ApplicationFiled: December 10, 2002Publication date: March 9, 2006Inventors: Pieter Van der Graaf, Christopher Peter Wayman, Andrew Baxter, Andrew Cook, Stephen Wong
-
Patent number: 6991916Abstract: Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof; (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).Type: GrantFiled: September 7, 2001Date of Patent: January 31, 2006Assignee: Pfizer Inc.Inventors: Neil Benson, Helen Frances Boyd, Leonard Gabriel Contillo, Ian Dennis Harrow, Stephen Charles Phillips, David Harlan Singleton, Peter Stacey, Roderick Thomas Walsh, Christopher Peter Wayman
-
Patent number: 6878529Abstract: Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).Type: GrantFiled: July 13, 2001Date of Patent: April 12, 2005Assignee: Pfizer Inc.Inventors: Ian Dennis Harrow, Peter Stacey, Roderick Thomas Walsh, Christopher Peter Wayman, Stephen Charles Phillips
-
Publication number: 20040254153Abstract: A method of treating a female suffering from FSD, in particular FSAD, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient.Type: ApplicationFiled: October 15, 2003Publication date: December 16, 2004Applicant: Pfizer IncInventors: Graham Nigel Maw, Christopher Peter Wayman
-
Publication number: 20040186046Abstract: The use of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Type 1 Diabetes. A method of treating Type 1 Diabetes in an individual suffering from Type 1 Diabetes, which method comprises administering to said individual an effective amount of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 12, 2004Publication date: September 23, 2004Applicant: Pfizer IncInventors: Gillian Munro Burgess, Earl Michael Gibbs, Christopher Peter Wayman
-
Publication number: 20040185094Abstract: A method of treating an individual is described. The method comprise delivering to the individual an agent that is capable of modulating an intermediate conductance calcium-activated potassium (IKCa) channel in the sexual genitalia of the individual; wherein the modulation of the IKCa channel by the agent is capable of mediating a relaxation of corpus cavernosal smooth muscle tone. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or exicipient.Type: ApplicationFiled: August 24, 2001Publication date: September 23, 2004Inventors: Graham Nigel Maw, Christopher Peter Wayman
-
Publication number: 20040176456Abstract: Use of an alpha-2-delta ligand, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of premature ejaculation.Type: ApplicationFiled: December 2, 2003Publication date: September 9, 2004Inventors: Charles Price Taylor, Andrew John Thorpe, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman, David Juergen Wustrow
-
Publication number: 20040132697Abstract: The present invention relates the use of &agr;1A and/or &agr;1L adrenergic receptor antagonists for the treatment of female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD) and/or female orgasmic disorder (FOD). The present invention also relates to a method of treatment of FSD, in particular FSAD and/or FOD, as well as to assays to screen for compounds useful in the treatment of FSD, in particular FSAD and/or FOD.Type: ApplicationFiled: October 31, 2003Publication date: July 8, 2004Applicant: Pfizer Inc.Inventors: Richard James Thurlow, Christopher Peter Wayman
-
Patent number: 6734186Abstract: A method of treating a female suffering from FSD, in particular FSAD, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient.Type: GrantFiled: November 8, 2000Date of Patent: May 11, 2004Assignee: Pfizer Inc.Inventors: Graham Nigel Maw, Christopher Peter Wayman
-
Publication number: 20040087561Abstract: Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compounds, for example PDE5 inhibitors, NEP inhibitors and lasofoxifene.Type: ApplicationFiled: December 4, 2003Publication date: May 6, 2004Inventors: Maria Isabel Gonzalez, Michael Higginbottom, Alisdair MArk Naylor, Robert Denham Pinnock, Martyn Clive Pritchard, Herman Thijs Stock, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
-
Publication number: 20030229002Abstract: The present invention relates to the effect of PDE11A modulation on male pro-fertility, male contraception, and female sexual dysfunction (FSD), specifically female sexual arousal disorder (FSAD), female orgasmic disorder (FOD), hypoactive sexual desire disorder (HSDD) or sexual pain disorders.Type: ApplicationFiled: February 14, 2003Publication date: December 11, 2003Applicant: Pfizer Inc.Inventors: Martyn Frank Burslem, Ian Dennis Harrow, Jeremy Lanfear, Stephen Charles Phillips, Christopher Peter Wayman
-
Publication number: 20030229001Abstract: A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.Type: ApplicationFiled: January 24, 2003Publication date: December 11, 2003Applicant: Pfizer Inc.Inventors: Alasdair Mark Naylor, Rachel Jane Russell, Stephen Derek Albert Street, Kim-Wah Tang, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
-
Publication number: 20030119714Abstract: The use of an inhibitor of a neuropeptide Y (NPY), preferably of a NPY Y1 receptor, which inhibitor is selective for an NPY or NPY Y1 receptor associated with male genitalia, in the preparation/manufacture of a medicament for the treatment or prevention of male erectile dysfunction (MED).Type: ApplicationFiled: December 12, 2001Publication date: June 26, 2003Inventors: Alasdair Mark Naylor, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
-
Publication number: 20020177689Abstract: Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof; (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).Type: ApplicationFiled: September 7, 2001Publication date: November 28, 2002Inventors: Neil Benson, Helen Frances Boyd, Leonard Gabriel Contillo, Ian Dennis Harrow, Stephen Charles Phillips, David Harlan Singleton, Peter Stacey, Roderick Thomas Walsh, Christopher Peter Wayman
-
Publication number: 20020169101Abstract: Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compounds, for example PDE5 inhibitors, NEP inhibitors and lasofoxifene.Type: ApplicationFiled: November 15, 2001Publication date: November 14, 2002Inventors: Maria Isabel Gonzalez, Michael Higginbottom, Herman Thijs Stock, Martyn Clive Pritchard, Robert Denham Pinnock, Pieter Hadewijn Van Der Graaf, Alisdair Mark Naylor, Christopher Peter Wayman
-
Publication number: 20020102707Abstract: Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).Type: ApplicationFiled: July 13, 2001Publication date: August 1, 2002Inventors: Ian Dennis Harrow, Peter Stacey, Roderick Thomas Walsh, Christopher Peter Wayman, Stephen Charles Phillips